<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Medical Appliances &amp; Equipment</title>
	<atom:link href="http://www.stockbloghub.com/category/medical-appliances-equipment/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALGN) Align Technology Posts Solid First Quarter Earnings</title>
		<link>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568</link>
		<comments>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:05:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[3M Company]]></category>
		<category><![CDATA[ALGN]]></category>
		<category><![CDATA[Align Technology Inc]]></category>
		<category><![CDATA[American Strategic Income Portfolio Inc]]></category>
		<category><![CDATA[ASP]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[MMM]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99568</guid>
		<description><![CDATA[Align Technology (ALGN) reported first quarter 2012 EPS of 26 cents, which was 30% higher than the year-ago level. Adjusting for certain one-time items, the adjusted EPS came in at 27 cents, beating the Zacks Consensus Estimate of 22 cents as well as the year-ago quarter adjusted EPS of 21 cents. The adjusted EPS also surpassed the company’s guidance range of 19?21 cents. Total revenue increased 28.7% year over year to $135.1 million in the quarter, exceeding the Zacks Consensus Estimate of $129 million and the company’s guidance of $125.4?$127.9 million. Total Invisalign clear aligner revenue came in at $123.3 million, up 17.6% year over year, driven by case shipments of 85.3 thousand (up 19.5%) during the quarter. Scanner and CAD/CAM services revenues were $11.8 million in the reported quarter, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/algn-align-technology-posts-solid-first-quarter-earnings/99568/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Medical Build on Alliance with Abbott Laboratories</title>
		<link>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648</link>
		<comments>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:03:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[FFR]]></category>
		<category><![CDATA[First Trust FTSE EPRA-NAREIT Glb Real Es]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99648</guid>
		<description><![CDATA[St. Jude Medical Inc. (STJ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories (ABT) by revealing the long-term Choice Alliance joint venture. This initiative provides St. Jude Medical the opportunity to incorporate Abbott&#8217;s drug-eluting stents with its cardiovascular, cardiac rhythm management and electrophysiology offerings. Both companies have agreed to endorse each other’s products to their respective customers. Further, Abbott has received the rights to promote St. Jude’s RadiAnalyze Xpress Measurement System and the ILUMIEN PCI Optimization System. This alliance is expected to benefit patient outcomes, as doctors will be able to combine Abbott’s XIENCE family of stents with St. Jude’s optical coherence tomography (OCT) and fractional flow reserve (FFR) know-how to widen the scope of clinical treatments. Abbott Laboratories is a global manufacturer of a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/stj-st-jude-medical-build-on-alliance-with-abbott-laboratories/99648/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Surgical Incorporated &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/04/26/isrg-intuitive-surgical-incorporated-bull-of-the-day-2/99638</link>
		<comments>http://www.stockbloghub.com/2012/04/26/isrg-intuitive-surgical-incorporated-bull-of-the-day-2/99638#comments</comments>
		<pubDate>Thu, 26 Apr 2012 18:09:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99638</guid>
		<description><![CDATA[We upgrade our rating for Intuitive Surgical, Inc. (ISRG) to Outperform. First quarter earnings per share of $3.50 beat the Zacks Consensus Estimate. Gynecology and prostatectomy procedures did well in 2011, as did certain emerging procedures. Recurring revenue continues to grow as a proportion of sales. In the interim, the installed base of Intuitive is expanding as more hospitals feel compelled to upgrade their technology. Overall, a proper valuation is appropriate given positive factors such as Intuitive&#8217;s leading position in robotic surgery, a growing list of emerging procedures, barriers to entry, sizeable cash balance and no debt. We like the company&#8217;s da Vinci system, particularly its unique status as an enabler of robotic, minimally invasive surgery. Our target price of $701 is based on a P/E of 48.2x our fiscal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/26/isrg-intuitive-surgical-incorporated-bull-of-the-day-2/99638/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Beats The Street &#8211; Raises Guidance</title>
		<link>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962</link>
		<comments>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962#comments</comments>
		<pubDate>Fri, 20 Apr 2012 17:26:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AF]]></category>
		<category><![CDATA[Astoria Financial Corporation]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CRM]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Salesforce.com]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=98962</guid>
		<description><![CDATA[St. Jude Medical, Inc. (STJ), a large-cap medical devices and technology development company, reported first quarter fiscal 2012 adjusted earnings of 86 cents beating the Zacks Consensus Estimate of 83 cents per share and surpassing the year-ago earnings of 80 cents per share. Adjusted earnings exclude extraordinary and one-time charges such as restructuring expenses to modernize manufacturing in the Cardiac Rhythm Management (CRM) segment. In the reported quarter, profit dropped 9% to $212 million (or 67 cents a share). Revenues St. Jude reported net revenues of $1,395 million, up 1% year over year, beating the Zacks Consensus Estimate of $1,383 million. Net sales rose 2% on constant currency basis. Healthy growth across the company’s smaller Atrial Fibrillation (AF) and Neuromodulation segments were largely offset by the decline in the core ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/20/stj-st-jude-beats-the-street-raises-guidance/98962/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Zacks Analyst Interviews</title>
		<link>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611</link>
		<comments>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611#comments</comments>
		<pubDate>Tue, 20 Mar 2012 02:13:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94611</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/19/mdt-medtech-industry-stock-outlook-march-2012-zacks-analyst-interviews/94611/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) MedTech Industry Stock Outlook &#8211; March 2012 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609</link>
		<comments>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609#comments</comments>
		<pubDate>Thu, 08 Mar 2012 19:28:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94609</guid>
		<description><![CDATA[Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure volume pressures. The difficult macroeconomic backdrop, pricing headwinds, austerity measures, reimbursement pressure, a still unstable job market and the impact of health care reform continue to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. With fewer patients going under the knife accompanied by concerns of overuse of devices, companies in the cardiovascular and orthopedic domain continue to grapple with tepid utilization. After having a buoyant first half, the MedTech sector went through a rough patch in the back half of 2011 given the weakened sector fundamentals, sluggish key end-markets ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/08/mdt-medtech-industry-stock-outlook-march-2012-industry-outlook/94609/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Buying NeuroNexus</title>
		<link>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142</link>
		<comments>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142#comments</comments>
		<pubDate>Thu, 23 Feb 2012 19:36:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=92142</guid>
		<description><![CDATA[Medical technology company Greatbatch (GB) is acquiring Michigan-based implantable medical device design firm NeuroNexus Technologies for roughly $12 million. The deal includes assumption of debt and future considerations (undisclosed). NeuroNexus, founded in 2004, specializes in high-value neural interface technology, components and systems for neuroscience and clinical markets. The entity possesses a vast portfolio of intellectual property, core technologies and capabilities to facilitate the development of innovative neural interface devices across a broad range of functions including neuromodulation, optical stimulation and targeted drug delivery applications. The acquisition is expected to boost Greatbatch’s foothold across cardiovascular and neuromodulation markets. The pooling of NeuroNexus’ technologies and Greatbatch’s capabilities will enable the combined entity to provide new world-class research products and systems to neuroscientists across the globe. Greatbatch expects the acquisition to be non-dilutive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/23/gb-greatbatch-buying-neuronexus/92142/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZMH) Zimmer Holdings Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/06/zmh-zimmer-holdings-earnings-scorecard/91349</link>
		<comments>http://www.stockbloghub.com/2012/02/06/zmh-zimmer-holdings-earnings-scorecard/91349#comments</comments>
		<pubDate>Mon, 06 Feb 2012 20:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[PowerShares Dynamic Semiconductors]]></category>
		<category><![CDATA[PSI]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91349</guid>
		<description><![CDATA[The announcement of Zimmer Holdings’ (ZMH) fourth quarter and fiscal 2011 results as on January 26, 2012, has led analysts to revise their estimates lower for the first quarter of fiscal 2012. The scenario, however, improves for the second half and onwards. Previous Quarter Highlights Zimmer reported an adjusted EPS of $1.36 during the fourth quarter of fiscal 2011, up 7.1% year over year and a couple of cents ahead of the Zacks Consensus Estimate. During the reported quarter, the company recorded $108.0 million provision for claims related to the Durom Acetabular component, which has been taken into account in the adjusted figure. For the full year, the adjusted EPS increased 10.9% to $4.80, surpassing the Zacks Consensus Estimate of $4.78. Revenues were $1.17 billion, up 2.9% on a reported basis ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/06/zmh-zimmer-holdings-earnings-scorecard/91349/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) St. Jude Medical Fourth Quarter 2011 Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302</link>
		<comments>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302#comments</comments>
		<pubDate>Mon, 06 Feb 2012 17:32:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91302</guid>
		<description><![CDATA[Medical devices major St. Jude Medical’s (STJ) fourth-quarter 2011 adjusted earnings per share of 86 cents beat the Zacks Consensus Estimate by a couple of cents and exceeded the year-ago earnings of 75 cents. Highlights from the Quarter Profit (as reported) for the fourth quarter slipped roughly 21% year over year to $163.4 million (or 51 cents a share) as higher sales were overshadowed by lofty special charges. Revenues rose 4% year over year to $1,406.9 million, beating the Zacks Consensus Estimate of $1,400 million. Double-digit growth across the company’s Atrial Fibrillation, Cardiovascular and Neuromodulation segments was partly masked by the decline in the core Cardiac Rhythm Management (“CRM”) division. Revenues from the CRM division fell 4% year over year, indicating sustained softness in the U.S. ICD market. ICD revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/06/stj-st-jude-medical-fourth-quarter-2011-earnings-scorecard/91302/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Surgical 2011 Fourth Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177</link>
		<comments>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177#comments</comments>
		<pubDate>Thu, 02 Feb 2012 19:41:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91177</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported favorable fourth-quarter 2011 results. Earnings per share came in at $3.75, beating the Zacks Consensus Estimate of $3.34 and the year-ago earnings of $3.02. Net income climbed 24.8% year over year to $151.2 million. Fourth Quarter Review Revenues increased 28% year over year to $496.8 million, beating the Zacks Consensus Estimate of $483 million. Instruments and accessories revenues were $196 million in the quarter, up 30% year over year. Worldwide procedures increased 27%. The company posted total systems revenue of $225 million in the quarter, up 27%. Services/Training revenues were $75 million in the quarter, up 24% year over year, primarily due to growth in the installed base of da Vinci Surgical systems. Agreement – Estimate Revisions Estimates for fiscal 2012 demonstrate an upward trend among ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/02/isrg-intuitive-surgical-2011-fourth-quarter-earnings-scorecard/91177/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Now is the Time to Buy Healthcare Stocks</title>
		<link>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149</link>
		<comments>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149#comments</comments>
		<pubDate>Thu, 02 Feb 2012 19:38:38 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91149</guid>
		<description><![CDATA[I’ve been talking a lot lately about the $4 trillion that’s about to fall into the laps of businesses in the healthcare sector due to the number of Baby Boomers who are now turning 65. And we know that the older we get, the more we spend on healthcare. Consider: The average senior takes between two and seven prescription medications. Two out of three seniors will suffer a physical or mental impairment. One out of three seniors will spend time in a nursing home. All of those things cost money – not to mention, chemotherapy, insulin, rehab stays, regular doctor appointments, weight loss programs and nutritional supplements. That’s why it’s a great time to put money to work in the sector. Revenue and earnings are going to explode higher in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/02/isrg-now-is-the-time-to-buy-healthcare-stocks/91149/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZOLL) ZOLL Medical Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2012/01/27/zoll-zoll-medical-corporation-bull-of-the-day-4/90966</link>
		<comments>http://www.stockbloghub.com/2012/01/27/zoll-zoll-medical-corporation-bull-of-the-day-4/90966#comments</comments>
		<pubDate>Fri, 27 Jan 2012 17:26:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90966</guid>
		<description><![CDATA[We retain our Outperform recommendation on ZOLL Medical Corp. (ZOLL) following its forecast-topping first quarter results. Revenues and earnings for the quarter beat the Zacks Consensus Estimates, driven by strong sales from the company&#8217;s LifeVest and temperature management businesses. The company witnessed healthy sales across the North American hospital and pre-hospital markets. We are pleased with ZOLL&#8217;s solid fundamentals and its broad product range. Moreover, its significant international presence should also drive growth. The company has completed multiple acquisitions and is seeking more such lucrative transactions to aid growth. Management&#8217;s outlook for fiscal 2012 is encouraging with sales are expected to grow at a healthy double-digit clip on the strength of the company&#8217;s core defibrillator business. ZOLL MEDICAL CO (ZOLL): Free Stock Analysis Report]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/27/zoll-zoll-medical-corporation-bull-of-the-day-4/90966/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Squarely Beats Earnings Expectations</title>
		<link>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562</link>
		<comments>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562#comments</comments>
		<pubDate>Wed, 25 Jan 2012 17:58:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90562</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported fourth quarter and fiscal 2011 earnings per share of $3.75 and $12.32, respectively, beating the Zacks Consensus Estimates of $3.34 and $11.89, respectively, while surpassing the corresponding year-ago results of $3.02 and $9.47. Revenues Intuitive reported revenues of $496.8 million and $1,757.3 million for the fourth quarter and fiscal 2011, respectively, up 28% and 24% year over year. The results beat the Zacks Consensus Estimates of $483 million and $1,741 million, respectively. On a segment basis, the company reported revenues from instruments and accessories of $196 million, up 30% year over year, in the fourth quarter. The growth was driven by a 27% year-over-year increase in da Vinci surgical procedures. Revenues from sales of systems were $225 million, up 27% year over year. The increase in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/25/isrg-intuitive-squarely-beats-earnings-expectations/90562/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) New Year Bets from MedTech</title>
		<link>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062</link>
		<comments>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062#comments</comments>
		<pubDate>Fri, 06 Jan 2012 21:03:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89062</guid>
		<description><![CDATA[Picking the right stock is never easy, especially in a difficult and volatile market. There are thousands of stocks to choose from and many investors eventually end up boiling the ocean. The U.S. economy continues to be cramped by a spate of headwinds including a still unstable job market, high debt, a soft housing sector and last but surely not the least, the European sovereign debt contagion, which have hit industries across the board. The recent EU summit did not bring out any concrete solution to staunch the debt crisis which began in Greece in 2009. The healthcare sector, traditionally revered as a safe haven for investors and one of the most preferred areas to take cover in the midst of market volatility, has been somewhat proved not immune to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/06/stj-new-year-bets-from-medtech/89062/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(STJ) Christmas Gift for the Ailing Heart</title>
		<link>http://www.stockbloghub.com/2011/12/14/stj-christmas-gift-for-the-ailing-heart/87908</link>
		<comments>http://www.stockbloghub.com/2011/12/14/stj-christmas-gift-for-the-ailing-heart/87908#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:48:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87908</guid>
		<description><![CDATA[Wilson Greatbatch, the self-professed &#8220;humble tinkerer&#8221; and a trailblazer in medical technology, invented the first implantable cardiac pacemaker in 1958 which kept the rhythm of millions of heartbeats and preserved countless lives across the planet. A couple of decades later, the first patient received an implantable defibrillator, the brainchild of Dr. Michel Mirowski, in 1980. But that took place decades ago and we have come a long way since then. Medical technology has advanced by leaps and bounds, revolutionizing the way medicine is practiced, in a hi-tech world. And what is more quintessential in this Faustian quest for good, and even better health, than taking care of the heart? There is a Chinese proverb that goes: “If you keep a green bough in your heart, the singing bird will come.” ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/stj-christmas-gift-for-the-ailing-heart/87908/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZOLL) ZOLL Medical&#8217;s AutoPulse Tapped by WSPR Szczecin</title>
		<link>http://www.stockbloghub.com/2011/11/30/zoll-zoll-medicals-autopulse-tapped-by-wspr-szczecin/87705</link>
		<comments>http://www.stockbloghub.com/2011/11/30/zoll-zoll-medicals-autopulse-tapped-by-wspr-szczecin/87705#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:57:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Koninklijke Philips Electronics NV]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PHG]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87705</guid>
		<description><![CDATA[Resuscitation devices maker ZOLL Medical (ZOLL) said that its new AutoPulse Plus cardiac support pumps has been bought by WSPR Szczecin, the biggest emergency service operator in Poland. The Polish entity has purchased 49 such devices to equip its fleet of ambulances. The innovative AutoPulse Plus pumps enables rescuers to defibrillate without stopping chest compressions for defibrillation. WSPR Szczecin selected the device based on positive user experience following a 12-month evaluation. The Massachusetts-based company also noted that WSPR Szczecin has initiated a program to upgrade to its new E Series Monitor/Defibrillator from the existing M Series platform. The E Series connects directly to AutoPulse Plus, which enables real-time integrated operation of these devices, thereby allowing consistent, uninterrupted chest compressions with timed shock delivery. Chest compressions, if stopped during defibrillation, results ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/zoll-zoll-medicals-autopulse-tapped-by-wspr-szczecin/87705/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HOLX) Hologic Launches C-View Software</title>
		<link>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723</link>
		<comments>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723#comments</comments>
		<pubDate>Wed, 30 Nov 2011 19:47:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Conceptus Inc]]></category>
		<category><![CDATA[CPTS]]></category>
		<category><![CDATA[Hologic Inc]]></category>
		<category><![CDATA[HOLX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87723</guid>
		<description><![CDATA[Hologic (HOLX), a leading player in the field of women’s health, has released its C-View synthesized 2D image reconstruction algorithm. This eliminates the requirement of a conventional 2D mammogram as a part of a 3D mammography (tomosynthesis breast cancer screening). The C-View software creates a 2D image from a single tomosynthesis, thus doing away with the need for additional 2D exposures. Hologic will feature the new algorithm along with its Selenia Dimensions breast tomosynthesis system at the annual meeting of the Radiological Society of North America (RSNA), currently underway in Chicago. Earlier this year, Hologic received approval from the US Food and Drug Administration (FDA) for its Selenia Dimensions 3D digital mammography tomosynthesis system. The device is capable of producing both 3D and conventional 2D images that can be used ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/holx-hologic-launches-c-view-software/87723/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic 2012 Second Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2011/11/28/mdt-medtronic-2012-second-quarter-earnings-scorecard/87649</link>
		<comments>http://www.stockbloghub.com/2011/11/28/mdt-medtronic-2012-second-quarter-earnings-scorecard/87649#comments</comments>
		<pubDate>Mon, 28 Nov 2011 20:34:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87649</guid>
		<description><![CDATA[The announcement of Medtronic’s (MDT) second quarter fiscal 2012 results, as on November 22, 2011, has led analysts to revise their estimates lower for the third quarter although the situation improves for the current fiscal. Second Quarter Highlights Medtronic reported an adjusted EPS of 84 cents in the second quarter of fiscal 2012, a couple of cents above the Zacks Consensus Estimate and the year-ago quarter. Revenues were $4.132 billion in the quarter, up 6% (up 3% at constant exchange rates or CER) year over year and higher than the Zacks Consensus Estimate of $4.066 billion. The company recorded 44% of its total sales from the international market during the quarter, which climbed 14% year over year (6% at CER) to reach $1.832 billion. As a result of the company’s focus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/mdt-medtronic-2012-second-quarter-earnings-scorecard/87649/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISRG) Intuitive Surgical 2011 Third Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2011/11/22/isrg-intuitive-surgical-2011-third-quarter-earnings-scorecard/86939</link>
		<comments>http://www.stockbloghub.com/2011/11/22/isrg-intuitive-surgical-2011-third-quarter-earnings-scorecard/86939#comments</comments>
		<pubDate>Tue, 22 Nov 2011 17:40:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86939</guid>
		<description><![CDATA[Intuitive Surgical (ISRG) reported favorable third-quarter 2011 results. Earnings per share came in at $3.05, beating the Zacks Consensus Estimate of $2.76 and the year-ago figure of $2.14. Net income climbed 41.3% year over year to $122.4 million. Second Quarter Review Revenues increased 30% year over year to $446.7 million, beating the Zacks Consensus Estimate of $416 million. Instruments and accessories revenues were $175.8 million in the quarter, up 38% year over year. Worldwide procedures increased 30%. The company posted total systems revenue of $199.1 million in the quarter, up 25%. Services/Training revenues were $71.8 million in the quarter, up 25% year over year, primarily due to growth in the installed base of da Vinci Surgical systems. Agreement – Estimate Revisions Estimates for fiscal 2011 demonstrate an upward trend among ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/22/isrg-intuitive-surgical-2011-third-quarter-earnings-scorecard/86939/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ZOLL) ZOLL Medical Corporation &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/11/21/zoll-zoll-medical-corporation-bull-of-the-day-3/87320</link>
		<comments>http://www.stockbloghub.com/2011/11/21/zoll-zoll-medical-corporation-bull-of-the-day-3/87320#comments</comments>
		<pubDate>Mon, 21 Nov 2011 18:47:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87320</guid>
		<description><![CDATA[We upgrade our recommendation on ZOLL Medical Corp. (ZOLL) to Outperform following its forecast-topping fourth quarter results. Revenues and earnings for the quarter outperformed the Zacks Consensus Estimates, driven by strong contributions from the company&#8217;s LifeVest and temperature management franchises, backed by higher sales in the North American hospital market. We are pleased with ZOLL&#8217;s solid fundamentals and its broad product range. Moreover, its significant international presence should also drive growth. The company has completed multiple acquisitions and is seeking more such lucrative transactions to aid growth. Management&#8217;s outlook for fiscal 2012 appears encouraging with sales are expected to grow at a healthy double-digit clip on the strength of the company&#8217;s core defibrillator business. Our price target of $53 is based on 27.3x our fiscal 2012 EPS estimate. ZOLL MEDICAL ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/21/zoll-zoll-medical-corporation-bull-of-the-day-3/87320/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Technology Industry Stock Outlook &#8211; November 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069</link>
		<comments>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069#comments</comments>
		<pubDate>Fri, 18 Nov 2011 18:52:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[THOR]]></category>
		<category><![CDATA[Thoratec Corporation]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87069</guid>
		<description><![CDATA[The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures, reimbursement pressure and the impact of health care reform continues to weigh on the medical devices industry, exacerbated by Europe&#8217;s sovereign debt plight. The beleaguered U.S. implantable defibrillator market continues to bother cardiac devices makers, as reflected by sustained implant volume pressure. On the other hand, companies in the orthopedic domain remain affected by a still choppy reconstructive implant market as they faced sustained pressure across hip, knee and spine businesses in the third quarter (albeit to a lesser extent vis-à-vis the sequentially prior quarter). Although a number of these issues are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/18/mdt-medical-technology-industry-stock-outlook-november-2011-industry-outlook/87069/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences Earns FDA OK on Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/11/10/ew-edwards-lifesciences-earns-fda-ok-on-trial-enrollment/86853</link>
		<comments>http://www.stockbloghub.com/2011/11/10/ew-edwards-lifesciences-earns-fda-ok-on-trial-enrollment/86853#comments</comments>
		<pubDate>Thu, 10 Nov 2011 21:23:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86853</guid>
		<description><![CDATA[Recently, Edwards Lifesciences Corporation (EW) received conditional approval from the US Food and Drug Administration for enrollment of a certain group of patients in the PARTNER II trial. The trial is studying the company’s next-generation Sapien XT transcatheter heart valve (THV). Under the new cohort (PARTNER II Cohort A) of the trial, patients (up to 2,000) with severe, symptomatic aortic valve stenosis, who are at higher risk of traditional open heart surgery, will be enrolled. They will be randomized to undergo either surgery or receive transcatheter valve replacement with Sapien XT (delivered either transfemorally or transapically). The primary endpoints will be a combination of mortality rate and major stroke at two years while valve performance and quality-of-life will be considered as secondary endpoints. The first cohort of the trial (PARTNER ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/10/ew-edwards-lifesciences-earns-fda-ok-on-trial-enrollment/86853/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Analyst Raises Shares to Outperform</title>
		<link>http://www.stockbloghub.com/2011/11/06/gb-greatbatch-analyst-raises-shares-to-outperform/86509</link>
		<comments>http://www.stockbloghub.com/2011/11/06/gb-greatbatch-analyst-raises-shares-to-outperform/86509#comments</comments>
		<pubDate>Sun, 06 Nov 2011 20:47:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86509</guid>
		<description><![CDATA[We upgrade our recommendation on Greatbatch (GB) to Outperform following its impressive third-quarter 2011 results. Adjusted earnings of 41 cents for the quarter outstripped the Zacks Consensus Estimate of 34 cents. Profit surged 17% year over year. Sales rose 3% year over year to $131.7 million, matching the Zacks Consensus Estimate. Revenues and profit were boosted by double-digit growth across the company’s Orthopedic and Vascular franchises, which offset the decline in the Electrochem unit. The company backed its revenue and earnings forecast for the full year. Greatbatch is a leading producer and supplier of batteries, capacitors and components used in implantable medical devices. The company’s top customers include Boston Scientific (BSX), Johnson &#38; Johnson (JNJ), Medtronic (MDT) and St. Jude (STJ). Greatbatch has been acquiring complementary businesses over the last ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/06/gb-greatbatch-analyst-raises-shares-to-outperform/86509/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALGN) Align Technology Beats The Street &#8211; Margins Lag</title>
		<link>http://www.stockbloghub.com/2011/11/04/algn-align-technology-beats-the-street-margins-lag/86166</link>
		<comments>http://www.stockbloghub.com/2011/11/04/algn-align-technology-beats-the-street-margins-lag/86166#comments</comments>
		<pubDate>Fri, 04 Nov 2011 18:41:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ALGN]]></category>
		<category><![CDATA[Align Technology Inc]]></category>
		<category><![CDATA[American Strategic Income Portfolio Inc]]></category>
		<category><![CDATA[ASP]]></category>
		<category><![CDATA[Danaher Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[DHR]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86166</guid>
		<description><![CDATA[Align Technology (ALGN) reported third quarter 2011 adjusted EPS of 27 cents, beating the Zacks Consensus Estimate of 20 cents as well as the year-ago quarter adjusted EPS by 2 cents. Reported EPS was also ahead of the company’s guidance range of 17-20 cents. Total revenue increased 31.3% year over year to $125.9 million, exceeding the Zacks Consensus Estimate of $122 million and the company’s guidance of $118-$123 million. Total Invisalign revenue came in at $114.3 million, up 19.1% year over year driven by case shipments of 79.4 thousand (up 19.8%) during the quarter. Align witnessed improved sales performance during the reported quarter. This positive growth was attributable to increased Invisalign case volume in North American Orthodontists and International doctors, strong growth of Invisalign Teen and higher earnings on the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/04/algn-align-technology-beats-the-street-margins-lag/86166/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Third Quarter 2011 Earnings Helped By Medical Business</title>
		<link>http://www.stockbloghub.com/2011/11/02/gb-greatbatch-third-quarter-2011-earnings-helped-by-medical-business/86281</link>
		<comments>http://www.stockbloghub.com/2011/11/02/gb-greatbatch-third-quarter-2011-earnings-helped-by-medical-business/86281#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:02:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86281</guid>
		<description><![CDATA[Greatbatch’s (GB) third-quarter fiscal 2011 adjusted (excluding one-time items) earnings per share of 41 cents outpaced both the Zacks Consensus Estimate and the year-ago adjusted earnings of 34 cents. Profit (as reported) soared 17% year over year to roughly $7 million (or 30 cents a share) owing to healthy sales from the New York-based company’s Orthopedic and Vascular businesses, supported by lower interest expense and tax. Revenues Revenues rose 3% year over year to $131.7 million, in line with the Zacks Consensus Estimate. Double-digit growth across the Orthopedic and Vascular franchises masked a decline in the Electrochem division. Foreign currency movements contributed $2 million to orthopedic revenues in the quarter. Segment Review Sales from the larger Greatbatch Medical division rose 6% year over year to $113.3 million as the company ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/gb-greatbatch-third-quarter-2011-earnings-helped-by-medical-business/86281/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences 2011 Fourth Quarter Earnings Scorecard</title>
		<link>http://www.stockbloghub.com/2011/10/31/ew-edwards-lifesciences-2011-fourth-quarter-earnings-scorecard/86162</link>
		<comments>http://www.stockbloghub.com/2011/10/31/ew-edwards-lifesciences-2011-fourth-quarter-earnings-scorecard/86162#comments</comments>
		<pubDate>Mon, 31 Oct 2011 15:47:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[NCA]]></category>
		<category><![CDATA[Nuveen California Municipal Value Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86162</guid>
		<description><![CDATA[The announcement of Edwards Lifesciences’ (EW) third quarter fiscal 2011 results as on October 19, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011. Third Quarter Highlights Edwards reported an adjusted EPS of 38 cents in the third quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, and missing the year-ago quarter’s adjusted EPS of 43 cents. Revenues increased 18.3% to $412.7 million, exceeding the Zacks Consensus Estimate of $405 million. Heart Valve Therapy remained the strongest segment at Edwards with an annualized growth of 22.7% to reach $246.1 million. Sales of surgical heart valves grew 7.7% to $163.5 million and transcatheter heart valves (THV) catapulted 69.1% to book $82.6 million. The other segments of the company, namely Critical Care, Cardiac Surgery ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/31/ew-edwards-lifesciences-2011-fourth-quarter-earnings-scorecard/86162/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLTM) Solta Medical Reports LipoSonix Approval</title>
		<link>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028</link>
		<comments>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028#comments</comments>
		<pubDate>Thu, 27 Oct 2011 17:26:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86028</guid>
		<description><![CDATA[Aesthetic laser treatments provider Solta Medical (SLTM) reported that Medicis Technologies Corporation, a unit of specialty pharmaceutical company Medicis Pharmaceutical Corporation (MRX), has won the U.S. approval for the second-generation LIPOSONIX system for non-invasive waist circumference reduction. Solta announced, in September 2011, the acquisition of Medicis Technologies Corporation in a deal worth $35 million. The acquisition, which is expected to be completed in fourth-quarter 2011, provides Solta with Medicis’ LIPOSONIX system which uses advanced non-invasive ultrasound energy to reduce abdominal fat. Under the agreement, Solta will pay $15 million to Medicis upon the completion of the deal. It will also pay up to $20 million contingent upon the attainment of near-term regulatory milestones in the U.S. Moreover, Solta would make additional future payments subject to the achievement of certain commercial ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/27/sltm-solta-medical-reports-liposonix-approval/86028/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences Corporation Earnings Preview</title>
		<link>http://www.stockbloghub.com/2011/10/18/ew-edwards-lifesciences-corporation-earnings-preview/85251</link>
		<comments>http://www.stockbloghub.com/2011/10/18/ew-edwards-lifesciences-corporation-earnings-preview/85251#comments</comments>
		<pubDate>Tue, 18 Oct 2011 17:11:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ACC]]></category>
		<category><![CDATA[American Campus Communities Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[NCA]]></category>
		<category><![CDATA[Nuveen California Municipal Value Fund Inc]]></category>
		<category><![CDATA[STS]]></category>
		<category><![CDATA[Supreme Industries Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=85251</guid>
		<description><![CDATA[Edwards Lifesciences Corporation (EW) is scheduled to release its third quarter fiscal 2011 results on Wednesday, October 19, 2011 after the market closes. The company is expected to earn 39 cents per share during the quarter on $405 million in revenues, according to the Zacks Consensus Estimate. The consensus estimate is lower that the year-ago quarter’s EPS of 43 cents. As per Edwards’ guidance (provided along with the second quarter results), adjusted EPS is expected in the range of 37?39 cents. Previous Quarter Highlights Edwards reported an adjusted EPS of 49 cents in the second quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, although exceeding the year-ago quarter’s adjusted EPS of 46 cents. Revenues increased 18.1% to $431.2 million, also ahead of the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/18/ew-edwards-lifesciences-corporation-earnings-preview/85251/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences Announces Share Buyback</title>
		<link>http://www.stockbloghub.com/2011/10/06/ew-edwards-lifesciences-announces-share-buyback/84653</link>
		<comments>http://www.stockbloghub.com/2011/10/06/ew-edwards-lifesciences-announces-share-buyback/84653#comments</comments>
		<pubDate>Thu, 06 Oct 2011 15:24:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[NCA]]></category>
		<category><![CDATA[Nuveen California Municipal Value Fund Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84653</guid>
		<description><![CDATA[Edwards Lifesciences Corporation (EW) recently announced a new share repurchase program worth $500 million. At the end of the second quarter of fiscal 2011, the company was left with $240 million of authorization. Edwards expects to repurchase approximately $100 million worth of additional shares during the third quarter of the current fiscal. Edwards exited the second quarter of fiscal 2011 with $468.2 million in cash and cash equivalents (up from $396.1 million at the end of December 2010) and total debt of $174.8 million. Free cash flow generated during the quarter was $42.1 million and the company anticipates it to be within the $190?$200 million level for the year. Moreover, 970,000 shares for $83.2 million were repurchased during the most recent quarter. While the latest share buyback program is an ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/ew-edwards-lifesciences-announces-share-buyback/84653/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EW) Edwards Lifesciences Sapien Under Centers for Medicare &amp; Medicaid Services NCA</title>
		<link>http://www.stockbloghub.com/2011/10/02/ew-edwards-lifesciences-sapien-under-centers-for-medicare-medicaid-services-nca/84430</link>
		<comments>http://www.stockbloghub.com/2011/10/02/ew-edwards-lifesciences-sapien-under-centers-for-medicare-medicaid-services-nca/84430#comments</comments>
		<pubDate>Sun, 02 Oct 2011 20:13:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ACC]]></category>
		<category><![CDATA[American Campus Communities Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[NCA]]></category>
		<category><![CDATA[Nuveen California Municipal Value Fund Inc]]></category>
		<category><![CDATA[STS]]></category>
		<category><![CDATA[Supreme Industries Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84430</guid>
		<description><![CDATA[Edwards Lifesciences (EW) received a major setback as the Centers for Medicare &#38; Medicaid Services (CMS) decided to initiate a National Coverage Analysis (NCA) of transcatheter aortic valve replacement (TAVR). As a result, the stock price of the company closed 6.58% lower on Thursday. According to the agency, it received a formal national coverage determination (NCD) request from the Society of Thoracic Surgeons (STS) and the American College of Cardiology (ACC). Edwards, a leading player in the field of heart valves and hemodynamic monitoring, issued a statement regarding the matter. The company was aware that CMS was considering initiating an NCA to decide on the reimbursement status of Sapien transcatheter heart valve (THV). Besides, it believes that a well-written NCD should ultimately be positive for patients. Current investor focus is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/02/ew-edwards-lifesciences-sapien-under-centers-for-medicare-medicaid-services-nca/84430/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WMGI) Wright Medical Group Gets a New CEO</title>
		<link>http://www.stockbloghub.com/2011/09/21/wmgi-wright-medical-group-gets-a-new-ceo/83685</link>
		<comments>http://www.stockbloghub.com/2011/09/21/wmgi-wright-medical-group-gets-a-new-ceo/83685#comments</comments>
		<pubDate>Wed, 21 Sep 2011 15:09:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83685</guid>
		<description><![CDATA[International orthopedic devices company Wright Medical Group (WMGI) recently reported that its Board of Directors chose Mr. Robert J. Palmisano as President and CEO, starting from September 17, 2011. Mr. David D. Stevens, who was interim President and CEO, will remain Chairman of the Board. Mr. Palmisano has notable expertise managing important listed medtech companies. Until recently, he was President and CEO of ev3. During his 2-year stint there, the market capitalization of ev3 jumped more than three fold, from about $800 million in April 2008 to $2,600 million in July 2010. Mr. Palmisano was President and CEO of IntraLase Corp. prior to joining ev3. Still earlier, he was President and CEO of MacroChem Corporation. He also served as President and CEO of Summit Technology Inc. until it was taken ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/wmgi-wright-medical-group-gets-a-new-ceo/83685/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SLTM) Solta Medical Buying Medicis Unit</title>
		<link>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359</link>
		<comments>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:05:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[Cutera Inc]]></category>
		<category><![CDATA[CUTR]]></category>
		<category><![CDATA[ELOS]]></category>
		<category><![CDATA[Medicis Pharmaceutical Corporation]]></category>
		<category><![CDATA[MRX]]></category>
		<category><![CDATA[Palomar Medical Technologies Inc]]></category>
		<category><![CDATA[PMTI]]></category>
		<category><![CDATA[SLTM]]></category>
		<category><![CDATA[Solta Medical Inc]]></category>
		<category><![CDATA[Syneron Medical Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83359</guid>
		<description><![CDATA[Aesthetic laser treatments provider Solta Medical (SLTM) has agreed to acquire Medicis Technologies Corporation, a unit of specialty pharmaceutical company Medicis Pharmaceutical Corporation (MRX), in a deal worth roughly $35 million. Under the agreement, Soltawill pay $15 million to Medicis upon the completion of the deal. It will also pay up to $20 million contingent upon the attainment of near-term regulatory milestones in the U.S. Moreover, Solta would make additional future payments subject to the achievement of certain commercial milestones. The acquisition, which is subject to customary closing conditions including antitrust clearance, is expected to close in fourth-quarter 2011. Solta plans to finance the transaction through its existing cash and credit facilities. The acquisition provides Solta with Medicis’ LIPOSONIX system, which uses advanced non-invasive ultrasound energy to reduce abdominal fat. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/sltm-solta-medical-buying-medicis-unit/83359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Grows Spinal Portfolio</title>
		<link>http://www.stockbloghub.com/2011/09/20/mdt-medtronic-grows-spinal-portfolio/83437</link>
		<comments>http://www.stockbloghub.com/2011/09/20/mdt-medtronic-grows-spinal-portfolio/83437#comments</comments>
		<pubDate>Tue, 20 Sep 2011 20:00:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AIS]]></category>
		<category><![CDATA[Antares Pharma Inc]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83437</guid>
		<description><![CDATA[Leading medical devices player, Medtronic’s (MDT) TSRH Spinal System has received 510 (k) clearance from the US Food and Drug Administration (FDA) to treat adolescent idiopathic scoliosis (AIS) with pedicle screws. The system, developed in collaboration with Texas Scottish Rite Hospital (TSRH), offers several types of pedicle screws, implants and other instruments to stabilize the spine. AIS is the most common pediatric spine condition, where many patients have curved spines. Moreover, if curvature of the spine becomes more pronounced as the patient grows old; it could harm the spinal cord. TSRH and CD Horizon pedicle screws are meant for posterior use in addition to fusion in the thoracolumbar spine when treating AIS. Spinal is the second biggest segment at Medtronic that generated $825 million in sales, flat compared to the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/mdt-medtronic-grows-spinal-portfolio/83437/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(WMGI) Wright Medical Group to Restructure</title>
		<link>http://www.stockbloghub.com/2011/09/20/wmgi-wright-medical-group-to-restructure/83539</link>
		<comments>http://www.stockbloghub.com/2011/09/20/wmgi-wright-medical-group-to-restructure/83539#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:47:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83539</guid>
		<description><![CDATA[International orthopedic devices company  Wright Medical Group (WMGI) recently reported that it is exercising a cost restructuring initiative to improve profitability, promote growth and strengthen cash flow, leading to enhanced shareholder value. The company believes that the early phase of this project will be concluded over the upcoming 9 months to be followed by more efficiency drives from 2012 onwards. According to Wright Medical Group, the restructuring initiative will lead to a more cost efficient enterprise, which will boost earnings in 2012. Furthermore, with a robust balance sheet, the company is well positioned to engage in further acquisitions. As per the plan, Wright Medical Group has launched several measures to curtail expenditure, including cutting down the range of its overseas product offering, streamlining its R&#38;D efforts and fine tuning factory ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/wmgi-wright-medical-group-to-restructure/83539/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medical Devices Stock Outlook &#8211; Sept. 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743</link>
		<comments>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743#comments</comments>
		<pubDate>Thu, 08 Sep 2011 19:53:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[Abiomed Inc]]></category>
		<category><![CDATA[ABMD]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BDX]]></category>
		<category><![CDATA[Becton Dickinson Company]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[CNMD]]></category>
		<category><![CDATA[Conmed Corporation]]></category>
		<category><![CDATA[Edwards Lifesciences Corporation]]></category>
		<category><![CDATA[EW]]></category>
		<category><![CDATA[Flaherty & Crumrine Preferred Income Opportunity F]]></category>
		<category><![CDATA[Intuitive Surgical Inc]]></category>
		<category><![CDATA[ISRG]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[PFO]]></category>
		<category><![CDATA[SMA]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>
		<category><![CDATA[Symmetry Medical Inc]]></category>
		<category><![CDATA[Thermo Fisher Scientific Inc]]></category>
		<category><![CDATA[TMO]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VOLC]]></category>
		<category><![CDATA[Volcano Corporation]]></category>
		<category><![CDATA[WMGI]]></category>
		<category><![CDATA[Wright Medical Group Inc]]></category>
		<category><![CDATA[Zimmer Holdings Inc]]></category>
		<category><![CDATA[ZMH]]></category>
		<category><![CDATA[ZOLL]]></category>
		<category><![CDATA[Zoll Medical Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82743</guid>
		<description><![CDATA[June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected to linger over the second-half of 2011, the industry is expected to fare relatively better this year thanks to several tailwinds and growth opportunities. Industry Dynamics The global medical devices industry is fairly large, intensely competitive and highly innovative, with estimated worldwide sales of more than $300 billion in 2011. The U.S. is the largest market, with estimated sales of roughly $95 billion in 2010. The highly-regulated medical devices industry is divided into different segments including Cardiology, Oncology, Neuro, Orthopedic and Aesthetic Devices. The U.S. medical devices ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/08/mdt-medical-devices-stock-outlook-sept-2011-industry-outlook/82743/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYBX) Cyberonics Stops Generator Shipment</title>
		<link>http://www.stockbloghub.com/2011/08/16/cybx-cyberonics-stops-generator-shipment/81410</link>
		<comments>http://www.stockbloghub.com/2011/08/16/cybx-cyberonics-stops-generator-shipment/81410#comments</comments>
		<pubDate>Tue, 16 Aug 2011 16:58:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81410</guid>
		<description><![CDATA[Recently, the leading neuromodulation company Cyberonics (CYBX) stopped shipment of two models of its Aspire platform generators. The company is currently retrieving the already sold but unused models namely No. 105 and 106.  The company has also suspended enrollment in its E-36 clinical trial pending resolution of this hardware related design issue. As a result of this massive set back, the company’s shares plunged more than 11% from the closing price of 12th August. The company’s decision is based on the realization that stimulation output current delivered to patients can be less than the output current programmed by a physician. The Vagus Nerve Stimulation (VNS) therapy System was approved for the treatment of medically refractory epilepsy in Europe in 1994 and in the US and Canada in 1997. Cyberonics is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/cybx-cyberonics-stops-generator-shipment/81410/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GB) Greatbatch Analyst Reaffirms Shares at Neutral</title>
		<link>http://www.stockbloghub.com/2011/08/09/gb-greatbatch-analyst-reaffirms-shares-at-neutral/80927</link>
		<comments>http://www.stockbloghub.com/2011/08/09/gb-greatbatch-analyst-reaffirms-shares-at-neutral/80927#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:25:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[GB]]></category>
		<category><![CDATA[Greatbatch Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80927</guid>
		<description><![CDATA[We reiterate our Neutral recommendation for Greatbatch Inc. (GB). Second-quarter fiscal 2011 earnings per share of 43 cents met the Zacks Consensus Estimate. Revenues rose 4% year over year to $146.5 million, topping the Zacks Consensus Estimate of $141 million. Sales were boosted by solid double-digit growth at the company’s Orthopedic franchise backed by favorable foreign exchange translation, which offset declines across other businesses. Greatbatch lifted its revenue and earnings forecast for the full year. Orthopedic revenues surged 24% in the quarter, fueled by customer product launches, market share gains as well as favorable foreign currency impact. Vascular Access sales fell 2% while CRM/Neuromodulation revenues edged down 1%, hurt by sustained pricing pressure and sluggishness in the CRM market. Revenues from Greatbatch’s Electrochem segment dipped 2% in the quarter. Greatbatch ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/gb-greatbatch-analyst-reaffirms-shares-at-neutral/80927/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KCI) Kinetic Concepts Aquired by Apax Partners and Two Canadian Pension Funds</title>
		<link>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075</link>
		<comments>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075#comments</comments>
		<pubDate>Thu, 14 Jul 2011 16:43:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AHS]]></category>
		<category><![CDATA[AMN Healthcare Services Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BLUD]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Immucor Inc.]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Total System Services Inc]]></category>
		<category><![CDATA[TSS]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79075</guid>
		<description><![CDATA[Private equity firm Apax Partners and two Canadian pension funds are set to acquire leading medical technology company Kinetic Concepts (KCI). The deal, including Kinetic&#8217;s outstanding debt, is valued at approximately $6.3 billion. As an independent global partnership, Apax exclusively focuses on long-term investment in growth companies. The acquisition of Kinetic is part of Apax’s intention to support deals in the financial &#38; business services, healthcare, media, retail &#38; consumer and technology sectors. However, probably its budget doesn’t permit such a big acquisition at this point, so Apax teamed up with the Canada Pension Plan Investment Board (CPPIB) and the Public Sector Pension Investment Board (PSP Investments) to get the deal done. As per the terms of the agreement, Kinetic’s shareholders will receive $68.50 in cash for each share of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/14/kci-kinetic-concepts-aquired-by-apax-partners-and-two-canadian-pension-funds/79075/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYBX) Cyberonics Stays Neutral</title>
		<link>http://www.stockbloghub.com/2011/07/11/cybx-cyberonics-stays-neutral/78605</link>
		<comments>http://www.stockbloghub.com/2011/07/11/cybx-cyberonics-stays-neutral/78605#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:54:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Cyberonics Inc]]></category>
		<category><![CDATA[CYBX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78605</guid>
		<description><![CDATA[We recently reiterated our Neutral recommendation on Cyberonics (CYBX) with a target price of $30.00, following our assessment of its fourth quarter 2011 results. Cyberonics reported fourth quarter 2011 EPS of 26 cents, which missed the Zacks Consensus Estimate of 29 cents and were well below the year-ago quarter adjusted EPS of 40 cents. The year-over-year decline was attributable to significant increase in income tax expense ($5.5 million in the reported quarter compared with the year-ago quarter level of $.03 million). Cyberonics develops and markets Vagus Nerve Stimulation (VNS) Therapy System, which is approved by the US Food and Drug Administration (FDA) for the treatment of refractory epilepsy and treatment-resistant depression (TRD). During the quarter, Cyberonics witnessed a continuous expansion in its top line, attributable to the company’s pioneer product, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/cybx-cyberonics-stays-neutral/78605/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARAY) Accuray Presents Promising CyberKnife Radiosurgery Data</title>
		<link>http://www.stockbloghub.com/2011/07/11/aray-accuray-presents-promising-cyberknife-radiosurgery-data/78691</link>
		<comments>http://www.stockbloghub.com/2011/07/11/aray-accuray-presents-promising-cyberknife-radiosurgery-data/78691#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:44:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78691</guid>
		<description><![CDATA[Leading radiosurgery systems maker Accuray Incorporated (ARAY) has presented encouraging new clinical data highlighting the benefits of its popular CyberKnife radiosurgery system and its recently acquired TomoTherapy radiation therapy system in treating a vast continuum of lung cancer patients. The data was presented at the World Conference on Lung Cancer (“WCLC”), which took place in Amsterdam, The Netherlands, between July 3 and 7, 2011. WCLC, hosted by the International Association for the Study of Lung Cancer (“IASLC”), is the leading international forum for lung cancer and thoracic oncology research and practice. IASLC is the only global organization dedicated to the study of lung cancer. The CyberKnife system delivers ablative doses of radiation to lung tumors with the highest levels of accuracy. Moreover, the TomoTherapy system delivers high quality intensity modulated ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/aray-accuray-presents-promising-cyberknife-radiosurgery-data/78691/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(RMD) ResMed Acquires BiancaMed</title>
		<link>http://www.stockbloghub.com/2011/07/07/rmd-resmed-acquires-biancamed/78563</link>
		<comments>http://www.stockbloghub.com/2011/07/07/rmd-resmed-acquires-biancamed/78563#comments</comments>
		<pubDate>Thu, 07 Jul 2011 16:59:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Resmed Inc]]></category>
		<category><![CDATA[RMD]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78563</guid>
		<description><![CDATA[Developer and marketer of medical equipments for treating sleep disordered breathing and other respiratory disorders, ResMed Inc. (RMD) recently acquired an Irish medical technology company BiancaMed Ltd. As per the terms of the deal, ResMed purchased all outstanding shares of BiancaMed. Financial terms of the deal were not disclosed. BiancaMed is a manufacturer and distributor of non-contact devices for monitoring sleep and breathing. The company’s leading product SleepMinder measures sleep and respiration with improved biometric software. The company’s proprietary technology motion sensor detects respiration and movement without physical contact. Resmed intends to integrate BiancaMed into its new Ventures and Initiatives unit.  ResMed estimates that the acquisition will dilute ResMed&#8217;s EPS by 4 cents in fiscal 2012. ResMed is one of the leading players in the generators, masks, and related accessories market, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/07/rmd-resmed-acquires-biancamed/78563/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Introduces Spinal Device</title>
		<link>http://www.stockbloghub.com/2011/07/06/mdt-medtronic-introduces-spinal-device/78477</link>
		<comments>http://www.stockbloghub.com/2011/07/06/mdt-medtronic-introduces-spinal-device/78477#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:30:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78477</guid>
		<description><![CDATA[Leading medical devices player, Medtronic (MDT), strengthened its Spinal portfolio with the launch of CD Horizon Fenestrated Screw Spinal System in Europe. The product will be used in combination with Fenestrated Screw Cement. Over the next few months, this product will be launched in India, Singapore and Australia. However, CD Horizon Fenestrated Screw Spinal System is not available in US. With CD Horizon Fenestrated Screw Spinal System, surgeons will be able to treat patients with poor bone quality that might arise from osteoporosis. Specially formulated bone cement can be injected into a patient’s vertebral body through the pedicle screw of the system that contains additional holes at the tip. During the last reported quarter, Medtronic’s Spinal segment generated $875 million in sales compared to $880 million in the year-ago period, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/mdt-medtronic-introduces-spinal-device/78477/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ARTC) NeuroTherm Buys ArthroCare Devices</title>
		<link>http://www.stockbloghub.com/2011/07/06/artc-neurotherm-buys-arthrocare-devices/78482</link>
		<comments>http://www.stockbloghub.com/2011/07/06/artc-neurotherm-buys-arthrocare-devices/78482#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:27:02 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[ARTC]]></category>
		<category><![CDATA[ArthroCare Corporation]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Smith & Nephew Plc]]></category>
		<category><![CDATA[SNN]]></category>
		<category><![CDATA[Stryker Corporation]]></category>
		<category><![CDATA[SYK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78482</guid>
		<description><![CDATA[Surgical products maker ArthroCare Corp (ARTC) has reportedly divested its Parallax and Contour product lines used in interventional spine surgeries to leading pain management products maker NeuroTherm, Inc. The Parallax products are used in a number of orthopedic procedures, including treatments for vertebral compression fractures (“VCF”), while Contour has been designed for vertebral body void (or space) creation. VCF is a condition characterized by the collapse of the vertebral bone. It may occur due to trauma or a weakened vertebra in patients with osteoporosis or metastatic cancer. Massachusetts-based NeuroTherm is a leading provider of radio frequency generators and related disposables used in chronic pain management. The company markets its products to interventional pain, interventional radiology, orthopedic and foot and ankle specialists globally. The acquisition of the Parallax and Contour products ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/artc-neurotherm-buys-arthrocare-devices/78482/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VAR) Varian Medical TrueBeam Lands in Sweden</title>
		<link>http://www.stockbloghub.com/2011/07/06/var-varian-medical-truebeam-lands-in-sweden/78480</link>
		<comments>http://www.stockbloghub.com/2011/07/06/var-varian-medical-truebeam-lands-in-sweden/78480#comments</comments>
		<pubDate>Wed, 06 Jul 2011 19:26:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78480</guid>
		<description><![CDATA[Leading integrated radiotherapy systems maker Varian Medical’s (VAR) coveted TrueBeam radiotherapy and radiosurgery system has made its Scandinavian debut as it was successfully placed at a leading hospital in Sweden. The advanced therapy system has begun treating cancer patients at Vasteras Hospital in Stockholm, the only hospital offering radiotherapy in Sweden. Doctors at Vasteras Hospital used the TrueBeam system to treat a 71-year old prostate cancer patient who became the first patient in Sweden to receive treatment with this novel therapy system. Prior to the arrival of the TrueBeam system, physicians at Vasteras Hospital have been treating 70 patients per day in two shifts. TrueBeam has enabled rapid treatment delivery while potentially allowing resumption of normal working patterns. Varian’s TrueBeam platform, launched in April 2010, is used in image-guided radiotherapy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/var-varian-medical-truebeam-lands-in-sweden/78480/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Expands Kyphon Portfolio</title>
		<link>http://www.stockbloghub.com/2011/07/03/mdt-medtronic-expands-kyphon-portfolio/78278</link>
		<comments>http://www.stockbloghub.com/2011/07/03/mdt-medtronic-expands-kyphon-portfolio/78278#comments</comments>
		<pubDate>Sun, 03 Jul 2011 19:25:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78278</guid>
		<description><![CDATA[Recently, Medtronic (MDT) launched two products to add to the Kyphon Balloon Kyphoplasty procedure (BKP), which is used for treating vertebral compression fractures (VCFs). The products are Kyphon Xpander II Inflatable Bone Tamp (IBT) and the Kyphon Inflation Syringe &#8211; the Kyphon Xpander II IBT System. The Kyphon Xpander II IBT System has been in use since November 2010. During the last reported quarter, revenues from BKP declined 9% (5% decline in the third quarter) and were flat on a sequential basis. In February 2011, results from three BKP studies were published that demonstrated the benefits of this technology Medtronic is confident of recording higher revenues from BKP in the forthcoming period based on positive coverage decision issued by Noridian Administrative Services in May. Moreover, data presented over the last ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/03/mdt-medtronic-expands-kyphon-portfolio/78278/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(KCI) Kinetic Concept&#8217;s V.A.C. Reaches UK</title>
		<link>http://www.stockbloghub.com/2011/07/01/kci-kinetic-concepts-v-a-c-reaches-uk/78209</link>
		<comments>http://www.stockbloghub.com/2011/07/01/kci-kinetic-concepts-v-a-c-reaches-uk/78209#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:38:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AHS]]></category>
		<category><![CDATA[AMN Healthcare Services Inc.]]></category>
		<category><![CDATA[KCI]]></category>
		<category><![CDATA[Kinetic Concepts Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78209</guid>
		<description><![CDATA[Recently, Kinetic Concept’s (KCI) latest Negative Pressure Wound Therapy (NPWT) product V.A.C. Via secured reimbursement status in UK and will be listed in the UK Drug Tariff, effective August 1, 2011. The company believes this reimbursement decision of the UK health authorities will prove beneficial for the healthcare community as well as patients given its lower pricing and positive clinical results from V.A.C. Via. Kinetic continuously seeks to develop and commercialize its V.A.C product line. During 2011, the company launched its next-generation NPWT product V.A.C. Via Therapy system in the US and in selected European markets. This is Kinetic’s first single-patient-use disposable system, which uses its proprietary Vortis micro-pump technology. Moreover, the company intends to expand the V.A.C. therapy product line with the launch of V.A.C. Ultra Therapy System in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/kci-kinetic-concepts-v-a-c-reaches-uk/78209/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VAR) Varian Medical TrueBeam Makes China Debut</title>
		<link>http://www.stockbloghub.com/2011/07/01/var-varian-medical-truebeam-makes-china-debut/78224</link>
		<comments>http://www.stockbloghub.com/2011/07/01/var-varian-medical-truebeam-makes-china-debut/78224#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:31:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Accuray Incorporated]]></category>
		<category><![CDATA[ARAY]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78224</guid>
		<description><![CDATA[Leading integrated radiotherapy systems maker Varian Medical (VAR) has achieved another key milestone as its popular TrueBeam therapy system has been successfully deployed at Shantou University Medical College&#8217;s affiliated cancer hospital, thereby becoming the first cancer treatment center in China to install this advanced system. Shantou University Medical College is a premier medical college and health research base in southern-eastern China. The TrueBeam system was donated to the hospital by private charitable organization Li Ka Shing (“LKS”) Foundation. It was dedicated in a special ceremony held at the affiliated hospital on June 28. TrueBeam was approved in China in early 2011. Varian recently secured the Japanese regulator&#8217;s clearance for the system. Introduced in April 2010, the TrueBeam platform is used in image-guided radiotherapy and radiosurgery to treat multiple cancer types. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/var-varian-medical-truebeam-makes-china-debut/78224/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic&#8217;s Bone Protein in Controversy</title>
		<link>http://www.stockbloghub.com/2011/06/30/mdt-medtronics-bone-protein-in-controversy/77970</link>
		<comments>http://www.stockbloghub.com/2011/06/30/mdt-medtronics-bone-protein-in-controversy/77970#comments</comments>
		<pubDate>Thu, 30 Jun 2011 21:28:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77970</guid>
		<description><![CDATA[Leading medical devices player Medtronic (MDT) has been put under the scanner based on some articles published on recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) in a recent edition of Spine Journal. According to a report issued in The Wall Street Journal (WSJ) on the Spine Journal finding, surgeons missed to mention the complications encountered with bone-growth protein in clinical trials. The WSJ reported that the Spine Journal found many serious complications such as sterility, infection, bone dissolution and worsened back and leg pain as well as cancer in 10-50% of patients who were treated with Infuse or a sister product in 13 clinical trials. These trials were funded by Medtronic and conducted by the surgeons during 2000 and 2010. Infuse Bone Graft constitutes rhBMP-2, which is applied to an absorbable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/30/mdt-medtronics-bone-protein-in-controversy/77970/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BSDM) BSD Medical Makes Classic Pact</title>
		<link>http://www.stockbloghub.com/2011/06/29/bsdm-bsd-medical-makes-classic-pact/77639</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bsdm-bsd-medical-makes-classic-pact/77639#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:54:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[AngioDynamics Inc]]></category>
		<category><![CDATA[ANGO]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSD Medical Corporation]]></category>
		<category><![CDATA[BSDM]]></category>
		<category><![CDATA[BSX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77639</guid>
		<description><![CDATA[Cancer treatment systems maker BSD Medical Corp (BSDM) has forged an exclusive distribution pact with Classic Medical Inc. (Classic Medical) for its MicroThermX Microwave Ablation system for soft tissue ablation (destruction). Classic Medical is a leading distributor of minimally-invasive surgical products with a rich history of selling state-of-the-art surgical devices made by some of the major medical companies in the U.S. Moreover, the entity has long-term associations with doctors, key opinion leaders and hospitals across the Southeastern U.S. Classic Medical has a dedicated sales force specialized in marketing surgical products for the interventional radiology market, the target area for BSD Medical’s ablation products. The deal provides it the rights to distribute the MicroThermX products in North Carolina, South Carolina, Georgia, Florida, Alabama and Tennessee. The agreement concludes BSD Medical’s efforts ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bsdm-bsd-medical-makes-classic-pact/77639/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MDT) Medtronic Actively Checks Diabetes</title>
		<link>http://www.stockbloghub.com/2011/06/27/mdt-medtronic-actively-checks-diabetes/77602</link>
		<comments>http://www.stockbloghub.com/2011/06/27/mdt-medtronic-actively-checks-diabetes/77602#comments</comments>
		<pubDate>Mon, 27 Jun 2011 18:51:21 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Appliances & Equipment]]></category>
		<category><![CDATA[Boston Scientific Corporation]]></category>
		<category><![CDATA[BSX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77602</guid>
		<description><![CDATA[In a positive development, research findings presented at a recent conference mirrors the effectiveness of Medtronic’s (MDT) insulin pump therapy for improved glucose control in type 1 diabetic patients. The company offers sensor-augmented insulin pump therapy that integrates continuous glucose monitoring (CGM) into one device. In the fourth quarter of fiscal 2011, revenues from Medtronic’s Diabetes segment increased 11% year over year (9% at CER) to $368 million driven by 20% growth in CGM sales and robust growth in global insulin pumps. Both its Veo and Revel pumps continued to perform well. During the last reported quarter, Medtronic launched the Enlite Sensor in more than 35 countries outside the US and expects it to drive growth in the CGM business in fiscal 2012. The product is an advanced glucose sensor ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/27/mdt-medtronic-actively-checks-diabetes/77602/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

